Citation Impact
Citing Papers
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
2011
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
The Ensembl Variant Effect Predictor
2016 Standout
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Breast cancer
2019 Standout
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
2012
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics
2016
DNA methylation age of human tissues and cell types
2013 Standout
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
2015 Standout
Ovarian cancer
2014 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Long Noncoding RNAs in Cancer Pathways
2016 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy–Current progress and future direction
2020
Live-cell phenotypic-biomarker microfluidic assay for the risk stratification of cancer patients via machine learning
2018
High-performance medicine: the convergence of human and artificial intelligence
2018 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Development of a Next-Generation Sequencing Method for BRCA Mutation Screening
2012
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1
2014
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
2013
PARP Inhibitor Treatment in Ovarian and Breast Cancer
2011
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error
2014
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
2016
Melanoma
2015
Coming of age: ten years of next-generation sequencing technologies
2016 Standout
When Is Hub Gene Selection Better than Standard Meta-Analysis?
2013
The complexity of prostate cancer: genomic alterations and heterogeneity
2012
Cisplatin: The first metal based anticancer drug
2019 Standout
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
2012
Artificial intelligence in healthcare
2018 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Long Noncoding RNA and Cancer: A New Paradigm
2017 Standout
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Cancer: Evolution Within a Lifetime
2014
Antisense transcription at the TRPM2 locus as a novel prognostic marker and therapeutic target in prostate cancer
2014
Bioorthogonal Labeling of Human Prostate Cancer Tissue Slice Cultures for Glycoproteomics
2017 StandoutNobel
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
2021 Standout
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
2011
Works of Darl D. Flake being referenced
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
2011
BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer
2012
Development and validation of a gene expression signature to distinguish malignant melanoma from benign nevi.
2014
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
2010